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Summary Ten previously untreated postmenopausal women with metastatic breast cancer, none of whom had
received prior systemic therapy, were treated with the luteinising hormone releasing hormone (LHRH)
analogue D-Ser(But)6, Azgly'0-LHRH (ICI 118630). Two obtained an objective partial remission, one in bone
metastases and one in lung metastases. One patient proved unassessable. Amongst the seven failures,
incomplete pituitary gonadotrophin suppression over the relatively short treatment period with the daily
injections was noted. The seven patients failing ICI 118630 received tamoxifen and two with high tumour
oestrogen receptor values responded.
LHRH analogues may provide a novel endocrine therapy for postmenopausal breast cancer although more
data are needed. In this study, the monthly depot injection proved superior to daily injections with regard to
gonadotrophin suppression, although it is not clear that this provides the mechanism of action.
A number of luteinising hormone releasing
hormone (LHRH) agonists are currently under-
going clinical trials in the treatment of advanced
breast cancer in premenopausal women (Klijn &
Jong, 1982; Nicholson et al., 1984; Tolis et al.,
1981) and prostate cancer in men (Tolis et al., 1984;
Borgman et al., 1982; Waxman et al., 1983; Allen et
al., 1983; Ahmed et al., 1983; Walker et al., 1983).
The preliminary endocrinological data appear
encouraging and show that LHRH agonists act to
down-regulate pituitary LHRH receptors and hence
cause a desensitisation of the pituitary gland to the
releasing properties of the drugs. This results in a
fall in circulating gonadotrophins: luteinising
hormone (LH) and follicle stimulating hormone
(FSH) and consequently a reduction of gonadal
steroidogenesis (Klijn & Jong, 1982; Nicholson et
al., 1984; Tolis et al., 1981, 1982; Borgman et al.,
1982; Waxman et al., 1983; Allen et al., 1983;
Ahmed et al., 1983; Walker et al;, 1.983). The ability
of these compounds to reduce; gonadal function is
often associated with tumour remissions (Klijn &
Jong 1982; Tolis et al., 1984; Borgman et al., 1982;
Waxman et al., 1983; Allen et al., 1983; Ahmed et
al., 1983). Interestingly, one LHRH agonist
leuprolide (D-Leu-6-des Glyt0-LHRH ethylamide)
has also been reported to induce short lived tumour
remissions in 12/31 postmenopausal women with
advanced breast cancer (Harvey et al., 1981). The
present study reports the clinical and endocrino-
logical effects of a potent LHRH agonist ICI
118630 (LHRH) analogue (D-Ser(Bu')6 Azgly10-
LHRH) in asymptomatic, postmenopausal women
with assessable breast cancer none of whom had
received previous systemic therapy.
Materials and methods
Study design
Consenting, previously untreated (except artificial
menopause) postmenopausal women with asymp-
tomatic but assessable metastatic breast cancer were
eligible for this study. Patients with acutely life
threatening disease or with bone disease deemed
close to fracture, spinal collapse or other serious
complications were excluded. Initially, local ethical
committee approval for drug usage was for one
month but this was lengthened to three months and
later indefinitely if the patients were deriving
benefit. Patients failing ICI 118630 were all
expected to proceed to tamoxifen therapy if
endocrine therapy was still appropriate. Tamoxifen
was expected to represent the best in 'conventional
hormone therapy' for breast cancer and, with
oestrogen and progesterone receptor status data, to
provide an insight as to whether tumour response
to ICI 118630 correlated with conventional
hormone response patterns.
D-Ser(But)6 Azgly'0-LHRH (ICI 118630; Zoladex)
D-Ser(Bu')6 Azgly'°-LHRH was supplied by
Imperial Chemical Industries (Macclesfield, UK) in
two forms. The first six patients received daily
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subcutaneous injections of the drug (250,ug in
citrate buffer; 0.5ml). The four later patients
received monthly subcutaneous injections of a
depot formulation containing 3.6mg of the drug. In
the depot formulation, ICI 118630 was incor-
porated in a lactide-glycolide co-polymer in the
form of a small cylindrical rod. This was injected
under local anaesthesia, through a 16 gauge needle
into the subcutaneous tissue of the anterior
abdominal wall.
Chemical endocrine data
Serum oestrone and DHA-sulphate were measured
using conventional radioimmunoassay techniques.
These assays featured tritiated radioligands and
liquid-phase antisera and used dextran-coated
charcoal to separate antibody-bound and free
steroid. Oestrone was extracted from plasma using
diethyl ether prior to assay, whilst DHA-S was
assayed directly in diluted plasma (Cameron et al.,
1975; Smith et al., 1975).
Serum cortisol was measured using a direct
radioimmunoassay procedure using an 12511
radioligand and a solid-phase antiserum (Riad-
Fahmy et al., 1979). Testosterone and adro-
stenedione both required pre-assay extraction with
diethyl ether and were measured in radioimmuno-
assays using 125I-radioligands and antisera coupled
to magnetisable, solid-phase supports (Dyas et al.,
1979; Read et al., 1962).
Oestradiol and progesterone were measured using
commercially available kits (Steranti Research Ltd;
Diagnostic Products Ltd). Luteinising hormone,
follicle stimulating hormone and prolactin were
measured using a double antibody radioimmuno-
assay procedure (Groom, 1977).
Results
Responders
Patient I Presented at age 58 years, six years post-
menopausal with inflammatory carcinoma of the breast
(staged T4N3M1). The methylene diphosphonate (MDP)
bone scan demonstrated multiple bone metastases which
were asymptomatic. Biopsy confirmed infiltrating ductal
carcinoma; the oestrogen receptor value (ER) was
75fmolmg-1 cytosol protein, the progesterone receptor
value (PR) lOfmolmg- . The patient received
radiotherapy to the breast and daily s.c. injections of ICI
118630. The patient's serial bone scans showed progressive
improvement over three months' treatment (Figure 1).
Local ethical committee approval for drug usage ceased at
three months and after day 89, the patient was placed on
tamoxifen (20mg orally twice daily). She remained well
until day 496 when a further MDP bone scan
demonstrated recurrence in the same bony sites. At this
time, plain X-rays and CT scanning of the 'hot' lumbar
vertebrae were diagnosed as typical of metastatic
involvement by a diagnostic radiologist quite independent
of this study.
Gonadotrophin data: At presentation serum LH/FSH
(IU -1) concentrations were raised (40/56) and showed
stimulation during early days (D) of treatment (D1,
+2h:>501>80) but by 12 days less stimulation was
noted (pre-injection: 5/9, +2h: 8/11) and suppression was
marked thereafter (D36, pre-injection: 8/13, +2h:<0.7/9).
Patient 2 Presented at age 49 as a premenopausal lady
with apparently early and localised breast cancer. She was
treated by mastectomy for infiltrating duct carcinoma.
The ER/PR status is unknown. Five years later, now three
years postmenopausal, the chest X-ray and later CT lung
scan (Figure 2) showed multiple pulmonary masses. She
was asymptomatic. MDP bone scanning and liver
ultrasound scans were clear, as was the clinical
examination. Therapy was commenced with ICI 118630
by monthly depot injection. The patient's pulmonary
metastases achieved a partial response (Figure 3), which
persists into the thirteenth month (at the time of writing)
and the therapy continues.
Gonadotrophin data: At presentation serum LH/FSH
values were raised (24/30). There was no evidence of early
gonadotrophin stimulation with this depot injection (D4,
21/18) but suppression was obvious at day 7 (16/14) and
was profound thereafter (D14, 1/4; D21, <0.7/1; D28,
<0.7/1; D42, <0.7/2; D56, <0.7/4).
Non responders
Patient 3 Presented at age 43 years with bilateral breast
cancer for which she was treated by bilateral mastectomy
and, although there was no apparent metastatic disease,
she underwent bilateral oophorectomy. There are no
ER/PR data. Sixteen years later, the patient developed a
bone relapse and extradural compression. She was treated
by local radiotherapy to the spine and ICI 118630 daily
s.c. injections. After four weeks of treatment the MDP
bone scan showed no response. Tamoxifen therapy was
substituted but serial MDP bone scanning demonstrated
progression.
Gonadotrophin data: Pre-treatment LH/FSH levels
were low (<0.7/3) but early stimulation was apparent
(DI +2h: >50/> 80). Over the period of study the effect
of the daily injection remained stimulatory, although this
effect became blunted with time (D16, pre-injection: 2/7,
+2h 12/12; D22 pre-injection: 4/8, +2h 12/11).
Patient 4 Presented at age 80 years with an advanced
primary breast cancer and asymptomatic assessable bone
metastases were diagnosed on MDP bone scanning. No
ER/PR data were available. The patient received ICI
118630 daily injections. After four weeks the bone scan
showed new metastatic deposits. Tamoxifen therapy was
substituted but further MDP bone scanning showed
progression.
Gonadotrophin data: Pre-treatment serum LH/FSH
concentrations were low (<0.7/0.5), showed elevation 2h
after the first injection (11/45) but thereafter remained
profoundly low (<0.7/3).
Patient 5 Presented at age 74 with locally advanced







Figure 1 Serial MDP bone scans before and during therapy - patient 1. To the right of the last scan are
shown the abnormal vertebral appearance on plain X-ray and CT scanning.906 P.N. PLOWMAN et al.
Figure 2 CT lung scan of patient 2 taken during
therapy.
brain and lung metastases. Treatment comprised whole
brain radiotherapy and daily ICI 118630 injections. After
4 weeks the lung metastases, as assessed by plain chest X-
rays, were worse. Treatment was changed to tamoxifen
and a partial response in the pulmonary metastases was
achieved and lasted for longer than one year. The primary
tumour mass also responded pari passu.
Gondatrophin data: Pre-treatment serum LH/FSH
concentrations were elevated (17/24) and rose 2h after the
first injection (47/52). The stimulatory effects of the daily
injections were still marked at one week and still just
apparent at one month (D28, pre-injection 5/8, +2h
9/12).
Patient 6 Presented at age 48 years with an apparently
localised breast carcinoma for which she received a radical
mastectomy. No ER/PR data were available. Twenty
years later she developed a s.c. chest wall mass (biopsy
proven carcinoma: ER 145 and PR 7fmolmg-1). The
MDP bone scan demonstrated bone metastases that were
clinically asymptomatic. Treatment was commenced with
ICI 118630 s.c. daily injections for 3 months. At this time
the MDP bone scan showed deterioration and tamoxifen
was substituted. Three months later the bone scan was
stable, the local disease improved and serum alkaline
phosphate had decreased. She was scored as a tamoxifen
responder.
Gonadotrophin data: Pre-treatment serum LH/FSH
concentrations were elevated (16/...), rose after the first
injection (+2h 40/43) but this stimulation was only
blunted over the first month (D28 pre-injection <0.7/5.4,
+2h 8.7/12.3). Hormone concentrations were not
obtained during the second and third months.
Patient 7 Presented at age 62 years with an apparently
localised breast cancer treated by mastectomy. The ER
was 30 and PR 28 fmolmg- 1. Two years later the patient
developed a painful right hip and the MDP bone scan
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Figure 3 (a) Chest X-ray picture of patient 2 prior to
therapy Arrows denote metastases. (b) Chest X-ray
same area as in (a) but after 5 months of therapy.
demonstrated multiple bony metastases Treatment with
radiotherapy to the hip and ICI 118630 monthly depot
injections was commenced. After 10 weeks of therapy, the
bone scan showed new metastases. Tamoxifen therapy
was substituted but 10 weeks later the bone scan showed
further bone metastatic progression.
Gonadotrophin data: Pre-treatment serum LH/FSH
values were elevated (24/30), showed no stimulation in the
early days of therapy and suppressed thereafter (DI4, 1/4,
D21, <0.7/1.2, D28, <0.7/1; D56, <0.7/4).
Patient 8 Presented at age 61 with a large left breast
carcinoma and asymptomatic but assessable metastases on
MDP bone scanning. No ER/PR data were available
Treatment was commenced with ICI 118630 depot
injections. The MDP bone scan after 4 months showed
progressive metastatic disease and the patient was treated
with tamoxifen. After two more months, the MDP bone
scan demonstrated further progression.
Gonadotrophin data: Pre-treatment serum LH/FSH
values were elevated (10/18), did not rise early (D4, 11/14)
and were low at day 14 (2/3) and thereafter completely
suppressed (D21, <0.7/1; D28, <0.7/1).
Patient 9 Presented at age 68 with an apparently
localised carcinoma of breast treated by mastectomy. No
ER/PR data were available. Two and a half years laterBREAST CANCER REMISSION WITH LHRH ICI 118630 907
pain developed in the pubis and the MDP bone scan
showed multiple bone metastases. Radiotherapy to the
pubis and ICI 118630 depot injections commenced. After
three monthly injections the MDP bone scan showed
progression. Tamoxifen therapy was substituted and 3
months later the bone scan showed progression.
Gonadotrophin data: Pre-treatment serum LH/FSH
values were elevated (31/32), did not rise early (D6, 22/14)
and were suppressed by one month (D29 3/7).
Unassessable
Patient 10 Presented at age 35 and was premenopausal
with an apparently localised carcinoma of the breast
treated by mastectomy. No ER/PR data were available.
Two years later the patient complained of backache. The
MDP bone scan did not suggest metastatic disease but
nevertheless the patient underwent oophorectomy. At age
45 years, the patient developed axillary nodal recurrence
that was biopsy proven (ER 661 and PR 0fmolmg-1).
ICI 118630 daily s.c. injections were commenced but
response could not be scored as radiotherapy to the area
was given.
Gonadotrophin data: Pre-treatment LH/FSH levels
were raised (28/46) and showed stimulation after
injections (D2, +2h: >50/ >80; D8, >50/43; D21, +2h
27/33; D28, +2h 33/32). Gonadotrophin suppression was
not achieved by 28 days in this patient.
Chemical endocrine data
Gonadotrophin data have been presented on each
individual patient. It is clear that the daily s.c.
injections have proved less satisfactory at effecting
gonadotrophin suppression within the first month
of treatment (Table I).
Serum levels of oestradiol, oestrone, proges-
terone, testosterone, DHASO4, androsternedione,
cortisol, prolactin, GH, ACTH were serially
monitored in all ten patients before and at several
(early, intermediate and late) time points during ICI
118630. These data show no change at any time
point.
Discussion
A preliminary report (Harvey et al., 1981) claimed
that 12/31 (40%) of postmenopausal women with
metastatic cancer benefited from leuprolide treat-
ment but these authors have never definitively
published their studies. However, the results are of
great interest because hypophysectomy has been
known to be effective therapy in postmenopausal
women with metastatic breast cancer and its mode
of action has never been satisfactorily explained.
In the non-randomised Guy's Hospital series
(Hayward et al., 1970), hypophysectomy proved
better than adrenalectomy and Henderson and
Canellos (1980) cite anecdotal evidence of a
response to hypophysectomy after adrenalectomy -
both suggesting the the mode of action was not via
the pituitary-adrenal axis.
With the availability of potent long acting
LHRH analogues and the discovery that they
induce down-regulation of pituitary gonadotrophin
receptors, came the opportunity to inhibit the
anterior pituitary secretion of gonadotrophins in
Table I Gonadotrophin levels at sampling time points during daily s.c.
injections of ICI 118630 and during the first month after depot injection.
Daily s.c. injection
n=6 LH (IU 1)±s.d. FSH (IU 1)±s.d.
Pretreatment 17+ 15 26+22
Dayl Pre 42+16 63+14
Post 48+4 67+14
1 week Pre 7+5 12+11
Post 18+20 17+ 15
3 weeks Pre 3+2 10+5
Post 13+8 15+10
4 weeks Pre 4+3 9+6
Post 11+12 13+10
Monthly depot injection n=4
Pretreatment 19+8 29+7
1 week 18+4 13+1
3 weeks 1+0.2 5+6
4 weeks 1+1 3+3908 P.N. PLOWMAN et al.
postmenopausal women with breast cancer without
affecting the other anterior pituitary hormones.
It is also possible that circulating pharmaco-
logical concentrations of a potent LHRH analogue
could theoretically have a direct effect on breast
cancer cells if they were to possess LHRH
receptors. There are some laboratory data which
demonstrate LHRH receptors in breast tumours
(Lamberts et al., 1982), and recently Eidine et al.
(1985) and Miller et al. (1985) have described
LHRH binding sites in human breast carcinoma
cells.
In the study reported here, two postmenopausal
women showed an objectively measured and
durable remission of the metastatic breast cancer
(in bones and lungs respectively) following therapy
with the potent LHRH analogue ICI 118630. One
of these responses was interpreted from the
disappearance of 'hot spots' from the technetium
methylene diphosphonate bone scan in the lumbar
spine - where plain X-rays and CT scanning had
demonstrated metastatic disease. This response on
bone scanning does not meet UICC criteria because
the UICC do not accept bone scan responses.
Profound suppression of gonadotrophin secretion
from the pituitary was achieved in both patients
and no other anterior pituitary hormone, nor
cortisol, oestrogens nor androgens were perturbed,
as measured by serial blood levels throughout the
treatment period. Seven patients failed to respond
but several points must be made which may be
relevant, if the mechanism of response to ICI
118630 is effected by suppression of circulating
gonadotrophin levels. The daily s.c. injection of ICI
118630 proved less successful in down-regulating
pituitary gonadotrophin secretion than the depot
formulation. This fact together with the finite
period allowed for drug administration by the local
ethical committee in the early part of the study
meant that, in several patients, the pituitary
gonadotrophin secretion still had not been sup-
pressed fully by the time the drug was stopped.
This last observation may confound the response to
subsequent tamoxifen, a manoeuvre that had been
deliberately built into the study design for non-
responders to ICI 118630. For example, although
two responders to tamoxifen were observed, three
patients had not fully suppressed their gonado-
trophins with daily s.c. ICI 118630. It is therefore
d,ifficult to interpret the tamoxifen cross-over data
ixi this trial.
Five patients with tumours known to be ER
receptor positive were entered into this study, but
little may be concluded concerning the relationship
of ER positivity to the response to LHRH
analogues. In patient 1, there was a good response
to ICI 118630 in a tumour which was ER/PR rich;
the ER/PR status of the other responder's tumour
is unknown. In the non-responders with tumours
very rich in ER/PR, circulating gonadotrophins
were not fully suppressed during the period of
study, although they may have been so during the
second and third months in patient 6. Both of these
patients responded to subsequent tamoxifen. In
patient 10 with a very rich ER positive tumour, the
metastatic disease became unassessable due to
elective radiotherapy. In patient 7 the ER/PR
values were modestly raised and she responded to
neither ICI 118630 nor tamoxifen. It remains
important to determine the relationship of tumour
response to LHRH analogues and the ER/PR
status and data on cross-over to tamoxifen in
failing patients.
The LH/FSH levels were initially raised in both
responding patients and, indeed, were high in all
patients studied except two: one of these, the oldest
patient studied (patient 4 - aged 80 years), had very
low pre-treatment gonadotrophin values that were
hardly stimulated with daily s.c. 118630 injections
and quickly became fully suppressed. If LHRH
analogues prove effective therapy in postmeno-
pausal breast cancer and if their mode of action
should prove to be mediated through effects on
pituitary gonadotrophin secretion, the physiological
decline in pituitary gland gonadotrophin hyper-
secretion with time after the menopause provides
another variable for consideration. The other
patient with low pre-treatment gonadotrophin
values (patient 3) had been subjected to artificial
menopause (bilateral oophorectomy) at a relatively
young age and it was 16 years following this when
she received ICI 118630. In complete contrast to
the 80 year old patient, this patient had an
enormous response to her first daily injection of
ICI 118630 and serum gonadotrophins were still
not fully suppressed after 22 daily injections.
In this study, the more recently introduced
monthly depot preparation of ICI 118630 proved
much more effective than the daily s.c. injection in
rapidly and completely suppressing pituitary
gonadotrophin secretion. By day 4 there was no
gonadotrophin hypersecretion and all four patients
showed full suppression by three weeks. It may
prove essential to analyse the endocrine and clinical
data side by side in a study such as this. Without
the endocrine data it is highly probable that
different and, perhaps wrong, conclusions would
have been drawn with regard to tumour response
and ER positivity and the tamoxifen cross-over
data.
It is concluded that the long acting, potent
LHRH analogue ICI 118630 is capable of inducing
remissions in metastatic breast cancer in previously
untreated postmenopausal women. The mechanism
of the response is unknown but serum concen-
trations of anterior pituitary hormone (other thanBREAST CANCER REMISSION WITH LHRH ICI 118630 909
gonadotrophin) and sex steroid blood levels are not
perturbed. Thus these other hormones are probably
not involved in the mechanism of drug action. If
the response is mediated by the inhibition of
pituitary gonadotrophin secretion then the true
response rate may be higher than the 2/9 reported
here as not all patients achieved full suppression in
this study. It may be pertinent to note that full
suppression was documented in both responders
reported here. The length of time from the
menopause, the pre-treatment LH/FSH levels and
the ER/PR concentrations in the tumour may be
possible predictive factors of a response. An
alternative possibility is that the long acting LHRH
analogues are directly influencing breast tumour
growth. The cross-over data to tamoxifen, amongst
those failing ICI 118630, requires further study.
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